ArticleIndian journal of clinical biochemistry : IJCB2012
Organ Specific Tumor Markers: What's New?
Article in Indian journal of clinical biochemistry : IJCB, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Serum CEA, CA19-9, and AFP as biomarkers for gastric cancer.Journal of medical biochemistry · 2026Article
- A review of clinical use of surface-enhanced Raman scattering-based biosensing for glioma.Frontiers in neurology · 2024Review
- Encapsulation and adhesion of nanoparticles as a potential biomarker for TNBC cells metastatic propensity.Scientific reports · 2023Article
- Proteomic Markers for Mechanobiological Properties of Metastatic Cancer Cells.International journal of molecular sciences · 2023Review
- Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates.Investigative and clinical urology · 2021Review
- Interfacial interactions of SERS-active noble metal nanostructures with functional ligands for diagnostic analysis of protein cancer markers.Mikrochimica acta · 2021Review
- Tandem microfluidic chip isolation of prostate and breast cancer cells from simulated liquid biopsies using CD71 as an affinity ligand.RSC advances · 2020Article
- False-positive elevated CEA during colon cancer surveillance: a cholecystitis case report diagnosed by PET-CT scan.Journal of surgical case reports · 2019Article
- Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.Frontiers in pharmacology · 2019Article
- Detection of a soluble form of CD109 in serum of CD109 transgenic and tumor xenografted mice.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor markers are molecules produced in the body in response to cancer. An ideal tumor marker should have high sensitivity and specificity, should be cheap, and should be easily detected in body fluids. Identification of novel markers is important and it is expected that with the advent of newer technologies, more reliable markers will be discovered. This review discusses the currently available tumor markers for different malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.